OpenAI trial live updates: Elon Musk returns to the stand

Elon Musk’s $134 billion lawsuit against Sam Altman, Greg Brockman, and Microsoft over OpenAI’s investments and nonprofit mission resumed Wednesday, with Musk back on the stand. The case centers on whether OpenAI violated its original mission to develop AI for humanity’s benefit, while OpenAI says the suit is an attempt to hinder its growth and support Musk’s xAI competitor. A nine-person jury has been selected, and the trial is expected to last three weeks.

Analysis

This is less a clean binary legal headline than a volatility event around AI governance premiums. The market should treat MSFT’s exposure as a second-order multiple risk: even if damages never materialize, any discovery that expands the record around control rights, exclusivity, or board influence could raise the probability of antitrust scrutiny and slow the normalization of OpenAI/Microsoft economics. That matters because the strategic value in AI has increasingly been capitalized into software and cloud names as a durable moat, so even a modest reassessment can compress multiple expansion rather than hit near-term earnings.

For TSLA, the direct P&L impact is negligible, but the litigation keeps xAI in the conversation as a credible competitor and fundraising vehicle. The more important effect is on talent allocation and partner bargaining: prolonged uncertainty around OpenAI’s governance can make frontier-model researchers more willing to hedge with multiple employers, while enterprise customers may diversify model providers to avoid single-vendor concentration. That is mildly negative for OpenAI’s implied win-rate and supportive for second-tier model hosts and infrastructure picks-and-shovels over the next 6-18 months.

The near-term catalyst path is event-driven: testimony, injunction requests, and any document disclosures can move MSFT and AI-adjacent names in sharp but temporary bursts over days to weeks. The bigger tail risk is not a courtroom loss; it is forced structural concessions that make OpenAI more expensive to partner with and less exclusive to distribute through Microsoft, which would lower the option value embedded in MSFT’s AI narrative. Conversely, if the case is dismissed or narrowed quickly, the setup becomes a volatility crush trade because the market will have priced in a governance discount that is difficult to justify absent hard evidence.

Key Decisions for Investors

• Short-term: buy MSFT downside protection into the next major testimony/document drop via 1-2 month puts or put spreads; the asymmetry is better on a vol spike than on directional conviction.
• If MSFT gaps lower on headline risk, fade the move with a 2-4 week call spread only if there is no evidence of exclusivity/antitrust discovery expansion; the thesis is mean reversion once damages look remote.
• Relative value: long AI infrastructure beneficiaries with less governance overhang versus MSFT on a 3-6 month horizon; the cleaner AI capex narrative should retain premium if legal noise persists.
• For TSLA, treat the case as a low-conviction sentiment catalyst only; avoid outright directional positioning, but consider a small long-vol structure if broader AI narrative risk spills into mega-cap tech beta.